Homepage 2019-01-02T21:13:43+00:00

How We Help

Donated to NET cancer research
Annual visitors to online resources
Annual patient email and phone inquiries
Patient & caregiver education sessions

NET Cancer is the FASTEST growing class of CANCER worldwide


Neuroendocrine Tumours (NETs) Overview

  • Neuroendocrine tumours (NETs) are abnormal growth of cells (neoplasms) that arise from cells of the diffuse neuroendocrine system.
  • NETs are considered complex tumours because both tumor growth and hormonal function must be addressed.
  • NETs are most common in the lung or gastrointestinal system, but they can also originate in other parts of the body such as the thyroid, thymus, pancreas, adrenals, paraganglia, ovaries and testes.
  • NETs are classified as functional (produce hormones that cause symptoms), or non-functional (may or may not produce hormones and do not cause hormonal symptoms).
  • The cause of NETs is currently unknown.

Contact Us For Live Support

Support Lines:


Toll Free: 1-844-628-6788

Latest CNETS Canada News

Toronto’s CN Tower Lights Up Black & White!

November 11th, 2018|0 Comments

November 10, 2018 - Toronto's CN Tower lights up black & white in honour of NET Cancer Awareness Day

Health Canada approves XERMELO™ (telotristat ethyl)

October 17th, 2018|0 Comments

Health Canada approves XERMELO™ (telotristat ethyl) for the treatment of adult patients suffering from refractory carcinoid syndrome diarrhea(1) "XERMELOTM is a novel, orally administered, inhibitor of the enzyme tryptophan hydroxylase and is designed to reduce [...]

ePatient Magazine – Focus on NETs

October 17th, 2018|0 Comments

The latest edition of the ePatient magazine has several articles that focus on Neuroendcorine Tumours (NETs). Check it out at: ePatient Magazine

Public Listings for Caprelsa

September 18th, 2018|0 Comments

Caprelsa (vandetanib) is indicated for the treatment of symptomatic or progressive Medullary thyroid cancer in adult patients with unresectable locally advanced or metastatic disease. Alberta Health Services has put the listing on their Outpatient Cancer [...]

Patient Input – Treatment with Telotristat

September 3rd, 2018|0 Comments

TELOTRISTAT is an adjunct to somatostatin analogue therapy for the long-term treatment of carcinoid syndrome to improve symptom control in adult patients with metastatic neuroendocrine tumours.The company who makes telotristat has applied to Health Canada [...]

A Common Classification Framework For Neuroendocrine Neoplasms

September 3rd, 2018|0 Comments

RESEARCH ARTICLE A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal Published in Modern Pathology - August 23, 2018 [...]

Donate to CNETS Canada